Pfizer signs USD530M agreement with Novavax for Matrix-M vaccine adjuvant technology

USA—Pfizer has entered into a strategic agreement with Novavax, a US-based vaccine technology company, in a deal valued at up to USD530 million.

The pharmaceutical giant will pay USD30 million upfront to secure non-exclusive rights to Novavax’s proprietary Matrix-M vaccine adjuvant, a specialized ingredient designed to strengthen and extend the body’s immune response when incorporated into injectable vaccine formulations.

Under the terms of this partnership, Pfizer will assume complete responsibility for developing and bringing to market any vaccine products that utilize Matrix-M technology.

Meanwhile, Novavax will handle the manufacturing and supply of the adjuvant to support Pfizer’s development efforts.

Beyond the initial payment, Novavax stands to receive up to USD500 million in development and sales milestone payments for products containing Matrix-M.

The company will also earn tiered royalties in the high single digits on vaccines that incorporate the adjuvant technology.

Novavax positions Matrix-M as a core growth driver

This agreement represents a significant milestone for Novavax as it focuses on Matrix-M as a central component of its future growth strategy.

John Jacobs, the company’s CEO, highlighted this direction during his presentation at the 2026 J.P. Morgan Healthcare Conference.

The company has already established similar partnerships with major pharmaceutical players including Sanofi and Takeda, as well as organizations such as the Serum Institute of India.

Novavax continues to pursue expansion within the injectables market by seeking additional material transfer agreements, viewing these arrangements as potential pathways to more substantial collaborative partnerships.

The company maintains its own robust late-stage vaccine pipeline, which includes candidates for seasonal influenza and a combination vaccine targeting both influenza and COVID-19.

Vaccine industry faces regulatory headwinds

Vaccines have served as a cornerstone of healthcare since Dr. Edward Jenner created the first vaccination in 1796.

Scientists have since developed immunizations against numerous infectious diseases, protecting billions of people worldwide from preventable illnesses.

However, the vaccine landscape now faces unprecedented challenges from shifting policy priorities at the highest levels of US government.

Robert F. Kennedy Jr., serving as US Health Secretary, has publicly questioned the benefits of vaccines and has implemented several controversial policy changes.

His administration has already dismantled long-standing vaccine recommendations, including the previous guidance that all infants receive hepatitis B vaccinations.

Kennedy also terminated the entire US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices panel, replacing members with individuals known for their vaccine skepticism.

This move has drawn widespread criticism from healthcare professionals across the industry.

mRNA technology funding experiences sharp decline

Kennedy has specifically targeted mRNA vaccine technologies, recently revoking $500 million in research grants dedicated to these innovations in an effort to reduce their development priority.

This decision has created substantial ripple effects throughout the sector.

According to GlobalData, venture financing for mRNA-based vaccines plummeted by 82 percent between 2023 and 2025, reflecting the chilling impact of these policy shifts on investor confidence and research momentum in this specialized field.